Recombinant Human LAGE3 Protein
Beta LifeScience
SKU/CAT #: BL-3918PS
Recombinant Human LAGE3 Protein
Beta LifeScience
SKU/CAT #: BL-3918PS
Collections: Other recombinant proteins, Recombinant proteins
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.
Product Overview
Tag | N/A |
Host Species | Human |
Synonym | CVG5, DXS9879E, DXS9951E, ESO3, ITBA2, EKC/KEOPS complex subunit LAGE3, L antigen family member 3, Protein ESO-3. |
Background | L antigen family member 3 (LAGE3) is a part of the CTAG family. LAGE3 is ubiquitously expressed in somatic tissues unlike the other family members, which are usually expressed only in testis and activated in a broad range of human tumors. LAGE3 is also highly conserved in mouse and rat, suggesting that the encoded protein is functionally significant. |
Description | LAGE3 Human Recombinant expressed in E. coli is a single polypeptide chain containing 166a.a. (1-143) and having a molecular weight of 17.2kDa. LAGE3 is fused to a 23a.a. His-tag at N-terminus and purified by unique purification methods. |
Source | E.coli |
AA Sequence | MGSSHHHHHH SSGLVPRGSH MGSMRDADAD AGGGADGGDG RGGHSCRGGV DTAAAPAGGA PPAHAPGPGR DAASAARGSR MRPHIFTLSV PFPTPLEAEI AHGSLAPDAE PHQRVVGKDL TVSGRILVVR WKAEDCRLLR ISVINFLDQL SLVVRTMQRF GPPVSR. |
Purity | >85% as determined by SDS-PAGE. |
Endotoxin | <1.0 EU per μg by the LAL method. |
Formulation | The LAGE3 solution (0.25mg/ml) contains 20mM Tris-HCl buffer (pH 8.0), 0.15M NaCl, 50% glycerol and 2mM DTT. |
Stability | Recombinant protein is stable for 12 months at -70°C |
Usage | For Research Use Only |
Storage | Store at 4°C if entire vial will be used within 2-4 weeks. Store, frozen at -20°C for longer periods of time. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA).Avoid multiple freeze-thaw cycles. |